Compliance of Familial Mediterranean Fever Patients With Regular Follow-up Visits and Associated Factors. Issue 1 (9th December 2020)

• Record Type: Journal Article
• Authors: Bilici Salman, Reyhan; Babaoglu, Hakan; Satiş, Hasan; Yapar, Dilek; Avanoglu Güler, Aslihan; Karadeniz, Hazan; Ataş, Nuh; Haznedaroğlu, Şeminur; Öztürk, Mehmet Akif; Göker, Berna; Tufan, Abdurrahman
• Is Part Of: Journal of clinical rheumatology. Volume 28:Issue 1(2022)
• Page Start: e77
• Page End: e80
• Publication Date: 2020-12-09
• Subjects: familial Mediterranean fever -- compliance -- treatment -- follow-up; Rheumatism -- Periodicals; Rheumatology -- Periodicals; Musculoskeletal system -- Diseases -- Periodicals; Musculoskeletal Diseases -- Periodicals; Rheumatic Diseases -- Periodicals; Rhumatisme -- Périodiques; Rhumatologie -- Périodiques; Appareil locomoteur -- Maladies -- Périodiques; Musculoskeletal system -- Diseases; Rheumatism; Rheumatology; Periodicals; 616.723005
• DOI: 10.1097/RHU.0000000000001632
• Languages: English
• ISSNs: 1076-1608

Abstract

Abstract : Background: Follow-up is crucial to detect asymptomatic complications of familial Mediterranean fever (FMF). The current European League Against Rheumatism recommendations state that patients with FMF should be evaluated at least every 6 months to monitor attacks, acute phase response, and proteinuria. Objectives: This study aimed to assess compliance of FMF patients with regular follow-up visits and the associated factors. Methods: Adult patients with a diagnosis of FMF who had their initial visit at least over 1 year ago were included. Demographic and socioeconomic data, family history, and comorbid diseases were obtained from medical records. The International Severity Score for FMF and the Autoinflammatory Disease Damage Index scores were calculated. We defined patients as "compliant with follow-up visits" both if they had at least 2 visits during the previous year and a compatible physician's assessment. The characteristics of the compliant and noncompliant patients were compared, and multivariable logistic regression analysis was used to determine the factors influencing visit compliance. Results: Four hundred seventy-four patients with FMF were included. Two hundred thirty (48.5%) were compliant, and 244 (51.5%) were noncompliant with follow-up visits. A family history of FMF in parents, the absence of a family history of FMF in siblings, treatment with biologic agents, concomitant medication use, multisite involvement during FMF attacks, and treatment satisfaction were independent predictors of visit compliance. Conclusions: Only half of the patients with FMF were compliant with follow-up visits. Better strategies should be implemented to increase the compliance of FMF patients. Identifying independent predictors would help to build one.